Several effective anti-inflammatory agents and bronchodilators are available for controlling mild or moderate asthma. However, despite the availability of long-acting muscarinic antagonists (LAMAs) (e.g., Boehringer Ingelheim’s Spiriva), long-acting beta2 agonist (LABA)/LAMA/inhaled corticosteroid (ICS) fixed-dose combinations (FDCs) (e.g., GlaxoSmithKline (GSK)’s Trelegy, Chiesi’s Trimbow), and novel biologics (e.g., AstraZeneca’s Fasenra, Teva’s Cinqair / Cinqaero, Sanofi / Regeneron’s Dupixent, GSK’s Nucala), there is still a need for effective therapies for severe disease, especially for patients whose symptoms are not adequately controlled with current therapies or who depend on frequent SABA and/or oral corticosteroid use to experience relief. This Unmet Need report provides quantitative insights into key treatment drivers and goals and the current level of unmet need in severe asthma, based on the perceptions of U.S. and European physicians. We analyze the commercial opportunities and how emerging therapies can capitalize on these opportunities.
QUESTIONS ANSWERED
- What are the drivers and goals in the treatment of severe asthma?
- Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for severe asthma?
- What are the prevailing areas of unmet need and opportunity in severe asthma?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European physicians for a hypothetical new drug for severe asthma?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 30 U.S. pulmonologists, 32 U.S. allergists, and 32 European pulmonologists fielded in December 2022.
Key companies: Amgen, AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, Regeneron, Roche, Sanofi
Key drugs: Dupixent, Fasenra, Nucala, Tezspire (tezepelumab), Xolair, LABA/ICS FDCs, LABA/LAMA/ICS FDCs
- Asthma - Unmet Need - Detailed, Expanded Analysis - Severe Asthma (US/EU)
- Unmet need - severe asthma - TPP simulator - March 2023
- Executive summary
- Introduction
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed pulmonologists' and allergists' prescribing decisions in severe asthma
- Importance of efficacy attributes to prescribing decisions in severe asthma: United States - pulmonologists
- Importance of efficacy attributes to prescribing decisions in severe asthma: United States - allergists
- Importance of efficacy attributes to prescribing decisions in severe asthma: Europe
- Importance of safety and tolerability attributes to prescribing decisions in severe asthma: United States - pulmonologists
- Importance of safety and tolerability attributes to prescribing decisions in severe asthma: United States - allergists
- Importance of safety and tolerability attributes to prescribing decisions in severe asthma: Europe
- Importance of convenience of administration attributes to prescribing decisions in severe asthma: United States - pulmonologists
- Importance of convenience of administration attributes to prescribing decisions in severe asthma: United States - allergists
- Importance of convenience of administration attributes to prescribing decisions in severe asthma: Europe
- Importance of nonclinical factors to prescribing decisions in severe asthma: United States - pulmonologists
- Importance of nonclinical factors to prescribing decisions in severe asthma: United States - allergists
- Importance of nonclinical factors to prescribing decisions in severe asthma: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in severe asthma: United States - pulmonologists
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in severe asthma: United States - allergists
- Stated vs. derived Importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in severe asthma: Europe
- Product performance against treatment drivers and goals
- Assessment of unmet need
- Opportunity analysis
- Target product profiles
- Appendix
Priyanka Barua
Debismitha Priyanka Barua, M.P.H., Healthcare Research & Data Analyst, Immune and Inflammation. Prior to joining Clarivate, Ms. Barua was an epidemiologist for the Massachusetts Department of Public Health. She holds a master’s degree in epidemiology and biostatistics from Boston University’s School of Public Health and a bachelor’s degree in molecular, cellular, and developmental biology from the University of Kansas.